Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helliwell

Showing results (1171-1180 of 1,256) with videos related to

Pageof 126
Sort By:
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Npj Antimicrobials and Resistance|May 17, 2024
Modelling the impact of wastewater flows and management practices on antimicrobial resistance in dairy farmsHenry Todman, Richard Helliwell, Liz King, et al.
BMJ Medicine|March 25, 2026
Trends and inequalities in advice and guidance versus direct referral in NHS primary care, 2015-23: population based studyKayleigh J Mason, Kelvin P Jordan, James Bailey, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Proceedings of the 2019 GRAPPA Collaborative Research Network MeetingRobin Waxman, Carmel Stober, Deepak R Jadon, et al.
Schizophrenia Bulletin|October 6, 2025
iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical TrialChristopher D J Taylor, Ben Helliwell, Rebecca Coleman, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Seminars in Arthritis and Rheumatism|February 7, 2024
Patients' perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working GroupLara S Chapman, Begonya Alcacer-Pitarch, John D Pauling, et al.
Annals of the Rheumatic Diseases|June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysisTommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Pageof 126

Showing results (1171-1180 of 1,256) with videos related to

Sort By:
Pageof 126
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Npj Antimicrobials and Resistance|May 17, 2024
Modelling the impact of wastewater flows and management practices on antimicrobial resistance in dairy farmsHenry Todman, Richard Helliwell, Liz King, et al.
BMJ Medicine|March 25, 2026
Trends and inequalities in advice and guidance versus direct referral in NHS primary care, 2015-23: population based studyKayleigh J Mason, Kelvin P Jordan, James Bailey, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
Proceedings of the 2019 GRAPPA Collaborative Research Network MeetingRobin Waxman, Carmel Stober, Deepak R Jadon, et al.
Schizophrenia Bulletin|October 6, 2025
iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical TrialChristopher D J Taylor, Ben Helliwell, Rebecca Coleman, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Seminars in Arthritis and Rheumatism|February 7, 2024
Patients' perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working GroupLara S Chapman, Begonya Alcacer-Pitarch, John D Pauling, et al.
Annals of the Rheumatic Diseases|June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysisTommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
The Journal of Rheumatology|February 16, 2021
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) MeetingCarmel Stober, Deepak R Jadon, April W Armstrong, et al.
Pageof 126